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Highlights: 
• A LC-MS/MS method was developed and validated for simultaneous determination of 
aspirin and salicylic acid in human plasma. 
• The accuracy and the precision of the method with one-step liquid-liquid extraction 
were excellent for both analytes. 
• The method was highly robust and suitable for the analysis of > 2000 samples in a 
pharmacokinetic study. 
• The present method can contribute to the improvement of ASP/SAL determination in 
patients under antithrombotic therapy.  
• The method can contribute to the reduction of the risk for ASP resistance associated 
with bioavailability/exposure issues. 
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Abstract  
A liquid chromatography-tandem mass spectrometry method was developed for the 
simultaneous determination of acetylsalicylic acid (ASP) and its major metabolite, salicylic 
acid (SAL) in human plasma. The method was validated. ASP and SAL were extracted by 
single-step liquid-liquid extraction using tert-butyl methyl ether. The ions were detected in 
multiple reaction monitoring mode at m/z 179.0/137.0 transition for ASP and m/z 136.9/93.0 
for SAL. The lower limit of quantification for ASP and SAL was 1 and 80 ng/ml, 
respectively. The method was successfully applied for the characterization of the plasma 
concentration levels of ASP and SAL after oral administration of Aspirin Protect 100 to 
healthy volunteers. The present method can contribute to the improvement of ASP and SAL 
determination in patients under antithrombotic therapy, and to the reduction of the risk for 
ASP resistance associated with bioavailability/exposure issues (non-compliance, misdosing, 
poor absorption). 
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1. Introduction 
Aspirin (ASP) is a well-known salicylate drug (Fig. 1), which is one of the least 
expensive and most widely used anti-inflammatory, analgesic and antipyretic agent [1]. In 
addition, ASP at low doses (<100 mg/day) is applied for thrombosis prophylaxis, because it 
selectively inhibits cyclooxygenase (COX)-dependent platelet aggregation [2]. The 
mechanism of action and the effects of ASP depend on the dose taken [3]. At low doses (30-
100 mg/day), ASP irreversibly acetylates COX-1, which is responsible for the synthesis of 
prostanoids and for the generation of thromboxane A2. The antithrombotic effect of ASP is 
attributed to the selective inhibition of COX-1 dependent production of thromboxane A2 in 
platelets [4,5]. High-dose ASP (2-4 g/day) inhibits both COX-1 and COX-2, blocks 
prostaglandin production, and displays anti-inflammatory, antipyretic and analgesic effects. 
At extremely high doses (6-8 g/day), ASP has been reported to be as effective as cortisone in 
treatment of rheumatic disorders [6]. ASP has a short half-life, approximately 15-20 min in 
plasma, because it is rapidly hydrolyzed by esterases to salicylic acid (SAL) (Fig. 1) [7,8]. 
SAL is metabolized to gentisic acid or biotransformed by conjugation with glycin or 
glucuronic acid [7]. SAL also displays some anti-inflammatory, antipyretic and analgesic 
activity; however, the pharmacological activity of SAL is far from that of the parent 
compound [9]. The efficacy and safety aspects of ASP therapy require the establishment of 
the optimal dose for the particular indication. Therefore, optimization of ASP dosing is 
essential for the avoidance of both adverse drug reactions and ASP resistance. Misdosing of 
patients appears to be rather frequent; 10-20% of patients with cardiovascular disease are 
resistant to ASP [10]. ASP resistance is the inability of ASP to protect patients from 
thrombotic complications, to cause a prolongation of the bleeding time, or to inhibit 
thromboxane biosynthesis [11,12]. One of the possible reasons of ASP failure is the reduced 
bioavailability of ASP which is induced by inadequate intake of ASP, inadequate ASP dosing, 
and reduced absorption or increased metabolism of ASP [12].  
The bioavailability of ASP can be monitored by the simultaneous determination of 
ASP and SAL plasma levels in patients, and the optimal ASP dosing can be tailored 
individually. Hereby the risk of the clinical atherothrombotic vascular events in patients can 
be reduced. In addition, the guideline of the European Medicines Agency on the investigation 
of bioequivalence requires the determination of plasma levels of both ASP and SAL for a new 
ASP formulation since 2010 [13]. For the measurement of salicylates, several techniques are 
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available, such as colorimetric, fluorometric, enzymatic, gas or liquid chromatographic assays 
[14]. Bioanalytical HPLC-UV methods have also been reported for the quantification of ASP 
and its metabolites [15-21]. However, the liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) offers the most sensitive and selective methods for measuring salicylates 
simultaneously from biological matrices. The number of the published LC-MS/MS methods 
that are suitable for the simultaneous determination of ASP and SAL from plasma is still 
limited. Bae et al. [22] applied sample preparation methods separately for the parent 
compound and its deacetylated metabolite, whereas others reported multi-step sample 
preparation (protein precipitation followed by a liquid-liquid extraction) [23], one-step solid-
phase extraction [24], or even direct injection of the supernatant of precipitated plasma into 
the LC-MS/MS system [25]. To the best of our knowledge, no published LC-MS/MS method 
with a one-step liquid-liquid extraction is available for the simultaneous extraction and 
quantification of ASP and SAL in human plasma. The main advantages of the present method 
over the previously published methods are the single-step liquid-liquid extraction, the better 
retention on the HPLC column to lower the risk of matrix effect, the more symmetric peak 
shapes and the inexpensive materials necessary. The aim of the current work has been the 
development of a sensitive, selective and economical LC/MS-MS method for assaying ASP 
resistance in patients.  
 
2. Experimental 
2.1. Chemicals and reagents 
ASP and SAL (analytical standards) were purchased from Sigma-Aldrich Inc. (St 
Louis, MO, USA), while ASP-d4 and SAL-d4 (2-hydroxybenzoic-3,4,5,6-d4 acid) (internal 
standards) were obtained from Toronto Research Chemicals Inc. (Toronto, Canada) and 
C/D/N Isotopes Inc. (Pointe-Claire, Canada), respectively. Tert-butyl methyl ether (TBME) 
(LiChrosolv) and acetic acid (glacial, 100% Suprapur) were procured from Merck Inc. 
(Darmstadt, Germany). Formic acid (puriss p.a., 98-100%) and potassium fluoride (ACS 
reagent, ≥99.0%) were purchased from Sigma-Aldrich Inc. Acetonitrile (ultra gradient HPLC 
grade) was from J.T. Baker (Deventer, The Netherlands). Blank human plasma was purchased 
from Sera Laboratories International Ltd. (Haywards Heath, United Kingdom). 
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2.2. Chromatographic conditions 
The Agilent 1100 series HPLC system consisted of a G1312A binary pump, a 
G1322A degasser, a G1329A autosampler and a G1330A autosampler thermostat. The HPLC 
column was an InertSustain C18 (2.1×75 mm, 3µm) (GL Sciences Inc., Nishi Shinjuku, 
Japan), kept at ambient temperature (23±3°C). Other HPLC columns tested for separation 
were Inertsil ODS-4 (2.1×75 mm, 3µm) (GL Sciences Inc.) and ACE-3 C18 (2.1×75 mm, 
3µm) (Advanced Chromatography Technologies Ltd., Aberdeen, UK). The HPLC mobile 
phases were Milli-Q water containing 0.2% formic acid (eluent A) and acetonitrile containing 
0.2% formic acid (eluent B). The analytes were eluted by a gradient program. After sample 
injection (0 min), a mixture of 80% eluent A and 20% of eluent B was linearly changed to a 
mixture of 35% eluent A and 65% of eluent B until 4.0 min. Then eluent B was linearly 
reversed back to 20% at 4.1 min. Finally, the initial combination of the eluents was kept up to 
6.5 min for equilibration of the column. The flow rate was set at 0.3 ml/min, and the injected 
sample volume was 10 µl. A diverter valve was used to discard the LC effluent during the 
first 2.5 min and the last 1.0 min of each chromatographic run. 
2.3. Mass spectrometric conditions 
The mass spectrometer was an API2000 triple quadrupole instrument equipped with 
an electrospray ionization (ESI) interface (Applied Biosystems, Toronto, Canada). Data were 
acquired and processed by the Analyst software (version 1.4.2). The source parameters, 
curtain gas, collision gas, ion spray voltage, source temperature, nebulizer gas and auxiliary 
gas were set at 30 psi, 3 psi, -500 V, 400 °C, 60 psi and 60 psi, respectively. The parameters 
of the mass spectrometer, declustering potential, entrance potential, collision energy, collision 
entrance potential and collision exit potential for ASP and ASP-d4 
were -15 V, -10 V, -10 V, -10 V and -4 V, respectively. These parameters for SAL and 
SAL-d4 were -60 V, -15 V, -42 V, -15 V and -4 V, respectively. Detection of the ions was 
performed in multiple reaction monitoring (MRM) mode, monitoring the transition of the 
m/z 179.0 parent ion to the m/z 137.0 product ion for ASP, the m/z 136.9 parent ion to the 
m/z 93.0 product ion for SAL, the m/z 183.0 parent ion to the m/z 141.0 product ion for 
ASP-d4 and the m/z 140.9 parent ion to the m/z 97.0 product ion for SAL-d4. The dwell time 
was 400 ms for all components. 
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2.4. Sample preparation 
The primary stock solutions of ASP and SAL for the preparation of calibrator (STC) 
and quality control (STQ) samples were prepared by separate weighing (MX5 balance, 
Mettler-Toledo International Inc., Switzerland). The primary stock solutions of ASP, SAL 
and internal standards (STC-ASP 100µg, STQ-ASP 200µg, STC-SAL 1mg, STQ-SAL 2mg, 
ASP-d4 50µg and SAL-d4 100µg) were prepared in acetonitrile containing 0.2% acetic acid. 
The working solutions used for spiking the calibrator and quality control (QC) samples were 
diluted separately by spiking an appropriate volume of the stock solutions to achieve the final 
concentrations for ASP, SAL and the internal standards. The dilutions were performed in 
acetonitrile containing 0.2% acetic acid. Stock and working solutions were stored at -20±5 °C. 
A simple liquid-liquid extraction method was followed for the extraction of ASP and 
SAL from human plasma. Because of the instability of ASP in plasma, potassium oxalate and 
sodium fluoride were used as anticoagulant, and the sample preparation was performed in ice-
water bath. The enzymes in human plasma were inhibited by 12% formic acid and 450 mg/ml 
potassium fluoride solution. The plasma and the 12% formic acid solution were mixed in 10:1 
volume ratio. An aliquot of 275 µl acidified human plasma, 10 µl of 450 mg/ml potassium 
fluoride solution, 10 μl of the corresponding standard working solution and 10 µl of IST 
solution were mixed. 2 ml of TBME was added to the samples, mixed (Vortex mixer, Velp 
Scientifica, England) and shaken (Multi-Tube vortexer, VWR International, USA) for 10 min. 
The samples were centrifuged (Harrier 18/80R centrifuge, Sanyo Electric Co., Japan) at 
3,500×g for 5 min at 4 °C. The upper phase (1.6 ml) was evaporated (Turbo Vap LV 
evaporator, Zymark Co., USA) and the evaporation residue was reconstituted in 250 µl of 
Milli-Q water (ELIX 3/Gradient A10 water purification system, Millipore Ltd., France) 
containing 0.2% acetic acid.  
2.5. Validation of the analytical method 
Validation of the procedure was performed in order to evaluate the method in terms of 
accuracy, precision, selectivity, sensitivity, linearity, recovery, matrix effect including the 
influence of haemolysis, carry-over, dilution effect and stability. The acceptance criteria were 
determined according to the FDA and EMEA guidance for bioanalytical method validation 
[26,27].  
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2.5.1. Selectivity 
Solutions of ASP and SAL were injected with the peak areas thereof equal to the non-
extracted highest calibrator. Solutions of ASP-d4 and SAL-d4 internal standards (IST) were 
injected with the peak areas thereof equal to that of IST in the samples. Each selectivity 
solution was injected separately to ensure that the analytes or ISTs did not contain any 
interfering impurity erroneously detected as the other compound. As a reference, for the 
quantification of any interference a lower limit of quantification (LLOQ) sample was also 
injected. Six blank human plasma samples from different lots (obtained under controlled 
conditions from different individuals) were tested for interference. The results were compared 
to those ones obtained for the LLOQ plasma sample. 
2.5.2. Calibration curve 
The nine-point calibration curves (for ASP: 1, 2, 5, 10, 20, 50, 100, 200 and 
500 ng/ml; and for SAL: 80, 160, 240, 320, 800, 1600, 2400, 3200, 8000 ng/ml) were 
constructed on the basis of the response ratio of the analyte to the corresponding IST versus 
the ratio of the analyte concentration to the corresponding IST concentration. The 
concentrations of ISTs in spiked plasma samples were 40 ng/ml for ASP-d4 and 400 ng/ml 
for SAL-d4. The weighting type was set to 1/y2.  
2.5.3. Accuracy and precision 
The intra-day accuracy and precision were determined by analyzing six replicates of 
ASP and SAL at four different QC levels in human plasma. The inter-day precision was 
determined by analyzing the four levels of QC samples in 3 different runs.  
2.5.4. Matrix effect and recovery 
For the investigation of matrix effect, the following samples were analyzed: Six 
different human plasma lots were used to prepare QC high and QC low samples (n = 6 for 
each concentration) with matrix. Post-extraction spiked samples were obtained by spiking 
blank plasma extract with the respective working solution. Matrix-free reference solutions 
were prepared at the concentration of the high and low QC samples, six each. 
For each individual plasma, the IST normalized matrix factor was calculated as 
follows (1, 2 and 3):  
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Matrix factor (Analyte) (1-6) = 
Peak area of Analyte (with matrix) (1-6) 
(1) 
Peak area of Analyte (without matrix) (average of 6) 
 
Matrix factor (IST) (1-6) = 
Peak area of IST (with matrix) (1-6) 
(2) 
Peak area of IST (without matrix) (average of 6) 
 
Matrix factor (IST normalized) (1-6) = 
Matrix factor of Analyte (1-6) 
(3) Matrix factor of IST (1-6) 
 
For the evaluation of matrix effect, the coefficient of variation (CV%) of the IST 
normalized matrix factors was calculated. The matrix effect on ionisation was accepted if the 
coefficient of variation (CV%) of IST normalized matrix factors was within 15%. 
For the determination of extraction recovery, the six different plasma lots (used for the 
determination of matrix effect) were investigated. The peak area of the analyte obtained for 
extracted blank samples spiked with the low and high QC solutions was compared to the peak 
area of the analyte obtained for the corresponding processed QC samples.  
 
Recovery [%]= 
(Peak area of the extracted QC sample) × 100 
(4) Peak area of the spiked blank extract 
 
For calculation of the recovery (4), the signal of the individual QC samples was 
compared to the mean of the reference samples. Finally, the individual recovery values were 
averaged. Acceptance criteria: The recovery optimally is >80%. Lower than 80% recovery 
could also be accepted on condition the precision for the six different blanks did not exceed 
15%. For the internal standards, the mean peak areas obtained for the QC samples were 
compared to those of the neat solutions reflecting the combined effect of the matrix and 
recovery. 
2.5.5. Influence of haemolysis 
For investigation of the potential effect of the haemolysis, QC samples were prepared 
in haemolysed plasma. Blank human oxalate/fluoride blood was collected freshly. The sample 
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was intensively mixed until haemolysis. 1.95 ml of blank oxalate/fluoride plasma was mixed 
with 0.05 ml of haemolysed human blood and then the sample was acidified. From this 
matrix, 6 replicates of QC samples at the medium concentration were prepared and analyzed.  
2.5.6. Stability 
Stability tests were conducted to evaluate the stability of the analytes in standard 
solutions, in whole blood and in plasma samples under different conditions. The stability of 
the analytes in the spiking solutions used for the preparation of the low and high QC samples 
was investigated after storage for 4 hours at room temperature and after 33-day and 90-day 
storage at -20 ± 5 °C in a deep freezer. The stability in whole blood stored in ice-water bath 
(1 hour) was performed by comparing the measured concentrations of the analytes in the 
stability samples with those in the freshly prepared samples. Short-term plasma stability in 
ice-water bath (4 hours), autoinjector stability (52 hours), freeze-thaw stability (3 cycles), 
long-term plasma stability (33 and 90 days at -70 °C) and re-injection stability (124 hours) 
tests were performed at the low and high QC levels.  
2.5.7. Dilution test 
To extend the upper limit of calibration, the possibility of dilution was investigated for 
samples containing ASP and SAL at high concentrations. Diluted high QC samples were 
prepared at the concentration of 2,000 ng/ml for ASP and 32,000 ng/ml for SAL. After the 
applied five times dilution, the concentrations of the diluted QC samples corresponded to the 
concentrations of the high QC samples.  
2.6. Pharmacokinetic analysis 
In the pharmacokinetic study, 33 healthy, mixed gender volunteers (18 to 45 years of 
age) were enrolled. The study protocol was approved by the National Institute of Pharmacy 
and Nutrition (Budapest, Hungary). For investigations, informed consent was obtained from 
the participants. The volunteers were administered orally by a single-dose Aspirin 
Protect 100 mg enteric coated tablet (Bayer Pharma AG) containing 100 mg of ASP. 
Volunteers were fasted for at least 10 hours before and 4 hours after drug administration. 
They were given standard diet 4, 6 and 12 hours after drug administration. The tablet was 
taken with 200 ml of tap water. For all subjects, the following blood samples were taken: pre-
dose (within 60 min) and at post-dose 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 
5.50, 6.00, 6.50, 7.00, 7.50, 8.00, 8.50, 9.00, 10.00, 11.00, 12.00, 13.00, 14.00, 16.00 and 
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24.00 hours. Blood samples (approximately 5 ml) were taken via an indwelling catheter from 
the forearm vein into a vacutainer tube. The blood samples were collected in tubes containing 
potassium oxalate and sodium fluoride as anticoagulant and esterase inhibitor, gently 
homogenized and cooled immediately in an ice-water bath until centrifugation. The blood 
samples were centrifuged within 30 min after blood taking at 1500g at 4 °C for 10 min to 
obtain plasma. Immediately after centrifugation, 1.5 ml of plasma was transferred into a 
polypropylene tube containing 0.15 ml of 12% formic acid solution in water to protect ASP 
from chemical hydrolysis. The tubes were capped, frozen immediately in dry ice and stored 
frozen (below -70 °C) until the analysis.  
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3. Results and discussion 
3.1. Optimizing the analytical system 
Optimization of the chromatographic method for the simultaneous determination of 
ASP and SAL in human plasma was challenging. i) ASP and SAL are polar compounds; 
therefore, their retention in conventional RP columns (C18, C8, phenyl stationary phases) is 
rather poor. ii) Complete separation of the analytes is essential, because ASP undergoes 
source fragmentation in the mass spectrometer and forms SAL. iii) In addition, highly 
different calibration ranges are required for ASP and SAL because of the endogenous SAL 
levels in blank human plasma [28,29]. iv) In the case of partial separation of the analytes, the 
much higher SAL levels can lead to ion suppression in the source of the mass spectrometer. 
The chromatographic separation was tested on several highly hydrophobic and inert 
HPLC columns (InertSustain C18, Inertsil ODS-4, ACE-3 C18) using various combinations 
of acetonitrile, methanol and additives (acetic acid, formic acid, ammonium formate buffer). 
The best retention, peak shapes and chromatographic resolution were achieved on the 
InertSustain C18 column with a flow rate of 0.3 ml/min and a total run time of 6.5 min. The 
best suitable mobile phase system for the gradient method was Milli-Q water and acetonitrile 
containing 0.2% formic acid. For optimization of the mass spectrometric parameters, a full 
scan mass spectrum was recorded for both ASP and SAL in negative ionization mode with 
electrospray ionization source. Multiple reaction monitoring scanning mode was used to 
obtain the best selectivity. No significant solvent adduct ions were observed. To detect as low 
as 1 ng/ml ASP level in human plasma, the maximal sensitivity of the mass spectrometer was 
required, whereas the limit of quantification for SAL was 80 times higher than for ASP. To 
prevent the ion saturation of the detector, non-optimal tuning parameters were used for the 
determination of SAL. Although the optimal declustering potential and collision energy for 
SAL would have been -28 V and -20 V, we used the parameters of -60 V and -42 V, 
respectively. 
 
3.2. Validation of the analytical method 
3.2.1. Selectivity and specificity 
The present method was selective, since no endogenous interfering peak was observed 
for ASP in the individual and pooled blank human plasma samples. However, trace levels of 
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SAL originating from the nutrients could not be avoided in the blank samples [28,29]. The 
retention times were stable, approximately 3.65 min for ASP and ASP-d4, and 4.0 min for 
SAL and SAL-d4, respectively. No carry-over was observed. The typical MRM 
chromatograms for ASP and SAL are shown in Fig. 2.  
3.2.2. Linearity 
The 9-point calibration curves proved to be linear in the 1 – 500 ng/ml concentration 
range for ASP and in the 80 – 8,000 ng/ml concentration range for SAL. The LLOQ was 
1 ng/ml for ASP and 80 ng/ml for SAL. The mean correlation coefficient (r) of the respective 
weighted calibration curves generated during the validation were 0.9985 (ranged between 
0.9974 and 0.9995) for ASP, and 0.9992 (ranged between 0.9986 and 0.9997) for SAL. 
3.2.3. Accuracy and precision 
The intra- and inter-day accuracy and precision data for ASP and SAL are presented in 
Table 1. The method fulfilled the postulated acceptance criteria concerning the intra-day and 
inter-day accuracy and precision defined in the FDA and EMEA guidances [26,27].  
3.2.4. Extraction recovery, matrix effect, influence of haemolysis and dilution 
effect 
The extraction recovery was determined by comparing extracted QC samples and 
post-spiked QC samples. The mean recoveries in the six individual blank human plasma for 
ASP were 88.4±6.5% at the concentration of 3 ng/ml and 91.1±3.7% at the concentration of 
400 ng/ml, whereas for SAL were 70.1±6.2% at the concentration of 240 ng/ml and 
82.3±4.2% at the concentration of 6,400 ng/ml. A negligible matrix effect was observed for 
both analytes and the internal standards. The CV% values of IST normalized matrix factors 
were 6.71% and 3.81% at the concentration of low QC and high QC samples for ASP, and 
7.09% and 3.07% for SAL, respectively. The combined effect of the matrix and the recovery 
for ASP-d4 and SAL-d4 was 90.5% and 84.1%, respectively.  
The peak area ratios obtained for the high and low QC samples were compared for 
pure plasma and plasma sample containing 2.5% haemolyzed blood. The haemolysis had no 
influence on the reliability of the quantification. The deviation for the standard/IST peak area 
ratios remained below the ±15% acceptance limit (deviation: +9.73% for ASP and -3.45% for 
SAL).   
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The upper concentration limits can be extended to 2,500 ng/ml for ASP and 
40,000 ng/ml for SAL by 5 times dilution with blank human plasma. The mean deviation 
from the nominal concentration was -11.5% and -9.4%, while the precision 5.0% and 3.7% 
for ASP and SAL, respectively. 
3.2.5. Stability 
In the different stability experiments carried out, viz. short-term plasma in ice-water 
bath, repeated freeze-thaw (3 cycles), autosampler, long-term plasma, whole blood, short-term 
benchtop solution and long-term solution, the results were found to be within the acceptable 
limits during the entire validation. The analytes and ISTs proved to be stable in working 
solutions for at least 4 hours at room temperature and 90 days in a freezer (-20±5 °C). Both 
ASP and SAL proved also to be stable in oxalate/fluoride human blood for at least 1 hour and 
acidified oxalate/fluoride human plasma for at least 4 hours kept in an ice-cooled water bath. 
ASP and SAL were also stable in frozen plasma during 3 freeze/thaw cycles and storage in an 
ultra-freezer for at least 90 days (below -70 °C). The plasma extract can be stored in the 
autoinjector at 4 °C for at least 52 hours prior to analysis. The samples can be re-injected 
together with the calibrators after storage at +4 °C for up to 124 hours. The main results of 
stability tests are shown in Table 2. 
 
3.3 Evaluation of the present analytical method 
Comparing to the published methods that are available for the simultaneous 
determination of ASP and SAL from human plasma, the present method was as sensitive as 
the most sensitive one in the literature [24]. In the method published by Xu et al. [25], protein 
precipitation by acidified acetonitrile was applied as sample preparation. It was a very simple 
procedure, however, the extraction recovery was variable over the concentration range. In the 
method described by Bae et al. [22], the samples for ASP and SAL were prepared separately 
by liquid-liquid extraction and protein precipitation, respectively. As this method used 
duplicate sample preparation for the analysis of the analytes, it was time consuming for both 
the sample preparation and the analysis. Nirogi et al. [23] developed a two-step extraction 
procedure for the simultaneous extraction of ASP and SAL. They used a protein precipitation 
method followed by a solvent extraction step for sample preparation. It produced consistent 
recovery over the measured concentration range; however, it was a two-step method and the 
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average recoveries were only 45±2.4% and 40±1.8% for ASP and SAL, respectively. Bharathi 
et al. [24] extracted ASP and SAL simultaneously from human plasma by a solid-phase 
extraction method. This method resulted in high extraction recovery with low variability over 
the detected concentration range (76.5-99.4% for ASP, and 72.6-101.5% for SAL); however, 
it was a less cost-effective sample preparation method due to the material necessary (SPE 
cartridges, organic solvents for the equilibration, washing and elution). The extraction 
recoveries in the present method by the one-step liquid-liquid extraction were at least as high 
and consistent as by the best working sample preparation method (solid-phase extraction). All 
of the organic solvent needed was 2 ml of TBME for one sample. Additionally, the method 
was highly robust, and suitable for the analysis of more than 2000 samples in a 
pharmacokinetic study. Thanks to the clean sample extracts and to the column washing step in 
the chromatographic gradient method, the matrix effect was negligible during the analysis of 
the samples throughout. Comparing the length of the stability of ASP in human plasma 
published in the literature [30], the present method provided the longest stability period (ASP 
was stable below -70 °C for at least 90 days). 
3.4. Pharmacokinetics in patients 
The present method was applied for the analysis of plasma samples obtained from 33 
healthy volunteers following oral administration of Aspirin Protect 100 mg enteric coated 
tablet. The mean plasma concentration – time profiles for ASP and SAL are shown in Fig. 3, 
and some relevant pharmacokinetic parameters are presented in Table 3.  
Based on the sensitivity and robustness, the method was found to be suitable for the 
accurate characterization of the plasma level curves for ASP and SAL in human. The 
variability of the results for ASP was approximately twice as high as for SAL. The most 
extreme pharmacokinetic curves are shown in Fig. 4. These volunteers presented about one 
order of magnitude difference between the Cmax values of the plasma level curves for ASP 
(Table 4), whereas less than 20% difference for SAL. The high variability of the plasma 
concentration levels for ASP can account for the inter-individual differences in the 
bioavailability of ASP which can be the source of the variability in pharmacological effects in 
patients. Furthermore, the simultaneous determination of ASP and SAL plasma levels can 
also reveal some reasons of ASP inefficiency, because the presence of SAL can prevent or 
even reverse the platelet function inhibiting the effect of ASP [31].  
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4. Conclusions 
A robust and sensitive LC-MS/MS method was developed and validated for the 
simultaneous determination of ASP and SAL in human plasma. Different calibration ranges 
were required for the analytes because of the endogenous SAL levels in blank human plasma, 
therefore non-optimal MS tuning parameters were used for the determination of SAL. The 
application of the non-optimal tuning parameters had no impact on the stability of the signal. 
The accuracy and the precision of the analytical method were excellent for both the parent 
compound and its deacetylated metabolite. All of the organic solvent required for the one-step 
liquid-liquid extraction was only 2 ml of TBME for one sample. The one-step sample 
preparation method as well as the robustness and specificity of the assay simplified the 
characterization of ASP and SAL plasma levels in volunteers. The present method can 
contribute to the improvement of ASP/SAL determination in patients under antithrombotic 
therapy and to the reduction of the risk for ASP resistance associated with 
bioavailability/exposure issues (non-compliance, underdosing, poor absorption). 
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Table 1 Intra- and inter-day accuracy and precision data for ASP and SAL. 
Analyte 
Nominal 
conc. 
[ng/ml] 
Mean 
measured 
conc. 
[ng/ml] 
Accuracy 
[%] 
Precision 
[%] 
Mean 
measured 
conc. 
[ng/ml] 
Accuracy 
[%] 
Precision 
[%] 
Mean 
measured 
conc. 
[ng/ml] 
Accuracy 
[%] 
Precision 
[%] 
Intra-day 
(n=6)   Day 1   Day 2   Day 3  
ASP 1.00 0.998 -0.2 11.7 0.954 -4.6 14.2 0.909 -9.1 14.8 
  3.00 2.93 -2.3 11.1 2.91 -3.0 6.5 2.81 -6.3 2.9 
  20.0 19.5 -2.5 2.8 19.3 -3.5 6.1 20.1 0.5 1.2 
  400 391 -2.3 4.7 377 -5.8 5.3 406 1.5 4.3 
             
SAL 80.0 78.4 -2.0 6.1 75.2 -6.0 10.0 84.1 5.1 5.3 
  240 243 1.3 5.6 233 -2.9 5.1 236 -1.7 2.5 
  800 776 -3.0 2.8 797 -0.4 4.7 753 -5.9 1.0 
  6400 6100 -4.7 1.5 6380 -0.3 3.2 6180 -3.4 3.7 
Inter-day 
(n=18)            
ASP 1.00 0.954 -4.6 13.3        
  3.00 2.88 -4.0 7.5        
  20.0 19.7 -1.5 4.0        
  400 391 -2.3 5.5        
             
SAL 80.0 79.2 -1.0 8.3        
  240 237 -1.3 4.8        
  800 775 -3.1 3.9        
  6400 6220 -2.8 3.4             
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Table 2. The main results of stability tests for ASP and SAL 
Stability test ASP SAL 
  
Nominal 
concentration 
[ng/ml] 
Measured 
concentration, 
mean [ng/ml] 
Deviation 
[%] 
Nominal 
concentration 
[ng/ml] 
Measured 
concentration, 
mean [ng/ml] 
Deviation 
[%] 
0 hour (initial) 
3.00 
2.95 -1.7 
240 
254 5.8 
4 hours in ice-water 
bath 
2.89 -3.7 252 5.0 
Third freeze-thaw 2.58 -14.0 228 -5.0 
52 hours in 
autosampler at +4 °C 
2.98 -0.7 253 5.4 
33 days below -70 °C 2.88 -4.0 238 -0.8 
90 days below -70 °C 3.02 0.7 243 1.3 
0 hour (initial) 
400 
379 -5.3 
6400 
6030 -5.8 
4 hours in ice-water 
bath 
371 -7.3 5827 -9.0 
Third freeze-thaw 369 -7.8 5660 -11.6 
52 hours in 
autosampler at +4 °C 
385 -3.8 6453 0.8 
33 days below -70 °C 388 -3.0 6000 -6.3 
90 days below -70 °C 375 -6.3 5850 -8.6 
0 hour in whole blood 
(initial) 
3.00 
3.41 
-7.6 240 
283 
-0.4 
1 hour in whole blood 
in ice-water bath 
3.15 282 
0 hour in whole blood 
(initial) 
400 
408 
11.3 6400 
7880 
2.1 
1 hour in whole blood 
in ice-water bath 
454 8042 
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Table 3. The mean pharmacokinetic parameters for ASP and SAL 
  ASP   SAL  SAL/ASP ratio 
 Mean SD CV% Mean SD CV% Mean SD 
Cmax [ng/ml] 696 421 60.5 4370 1230 28.1 6.28 2.92 
AUC(0-t) [ng*h/ml] 785 389 49.5 17800 5000 28.1 22.7 12.9 
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Table 4. Pharmacokinetic parameters of volunteer-3 and volunteer-29 
Volunteer 3 29 
ASP   
Cmax [ng/ml]  1750 189 
AUC(0-t) [ng*h/ml] 1290 139 
SAL   
Cmax [ng/ml] 5350 4590 
AUC(0-t) [ng*h/ml] 16300 20500 
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Figure captions: 
Figure 1. Chemical structure of aspirin, salicylic acid and their deuterated analogues 
(aspirin-d4 and salicylic acid-d4) 
Figure 2. Typical MRM chromatograms for ASP, SAL and ISTs of blank human plasma (A), 
LLOQ sample (B), ULOQ sample (C) 
Figure 3. The average plasma concentrations of ASP and SAL (mean±SD, n=33) in 
volunteers administered with 100 mg Aspirin Protect 
Figure 4. Individual pharmacokinetic curves of volunteer-3 and volunteer-29 
 





